HLB Life Science CO.,LTD. Logo

HLB Life Science CO.,LTD.

Develops anti-cancer drugs and distributes IVD medical devices and lab supplies internationally.

067630 | KO

Overview

Corporate Details

ISIN(s):
KR7067630004
LEI:
Country:
South Korea
Address:
경기도 화성시 동탄첨단산업1로 51-9 8층(영천동,엠타워지식산업센터), 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HLB Life Science Co., Ltd. is a specialized pharmaceutical and biotechnology firm operating with a dual focus. The company is dedicated to the development of innovative and differentiated anti-cancer medications as part of the broader HLB Group's global oncology strategy. Concurrently, its Medicare business develops, manufactures, and distributes a range of products including in-vitro diagnostic (IVD) medical devices, quasi-drugs, research reagents, and laboratory supplies. The company serves both domestic and international markets, providing healthcare solutions that span from diagnostics to therapeutics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.0 MB
2025-08-01 00:00
M&A Activity
[기재정정]주요사항보고서(회사합병결정)
Korean 56.6 KB
2025-08-01 00:00
M&A Activity
기타주요경영사항 (회사 합병결정 철회)
Korean 4.1 KB
2025-07-10 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 7.1 KB
2025-06-19 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 141.4 KB
2025-06-19 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 110.7 KB
2025-05-29 00:00
Capital/Financing Update
전환가액의조정 (제13회차)
Korean 10.7 KB
2025-05-19 00:00
M&A Activity
[기재정정]주요사항보고서(회사합병결정)
Korean 81.4 KB
2025-05-19 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 12.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-15 00:00
Delisting Announcement
기타시장안내 (에이치엘비생명과학 9WR 신주인수권 행사기간 만료 및 상장폐지 예고)
Korean 3.4 KB
2025-04-10 00:00
Related Party Transaction
임원ㆍ주요주주특정증권등거래계획철회보고서
Korean 16.1 KB
2025-04-10 00:00
Share Issue/Capital Change
전환가액의조정 (제14회차)
Korean 10.3 KB
2025-04-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 83.0 KB
2025-04-07 00:00
Capital/Financing Update
전환가액의조정 (제11회차)
Korean 12.0 KB

Automate Your Workflow. Get a real-time feed of all HLB Life Science CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Life Science CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Life Science CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.